Les Tillack
CEO
Healthcare
luinabio
Australia
Biography
Working for Progen Pharmaceuticals for 11 years prior to becoming CEO of LuinaBio (previously PharmaSynth) in 2009. During his time at Progen, Les has worked with and overseen Progen’s anti-cancer drug PI-88s progression from preclinical to phase 3 manufacture. He has also been responsible for the tech transfer and manufacture of many client products for both clinical applications and marketed products. Les holds a Bachelor of Science in microbiology and a Bachelor of Engineering in Chemical Engineering. Prior to commencing with Progen, Les spent 11 years working in clinical pathology for Drs Sullivan and Nicolaides Pathologists and has worked on various research projects for both the Department of Primary Industries and the University of Queensland.
Research Interest
Working for Progen Pharmaceuticals for 11 years prior to becoming CEO of LuinaBio (previously PharmaSynth) in 2009. During his time at Progen, Les has worked with and overseen Progen’s anti-cancer drug PI-88s progression from preclinical to phase 3 manufacture. He has also been responsible for the tech transfer and manufacture of many client products for both clinical applications and marketed products. Les holds a Bachelor of Science in microbiology and a Bachelor of Engineering in Chemical Engineering. Prior to commencing with Progen, Les spent 11 years working in clinical pathology for Drs Sullivan and Nicolaides Pathologists and has worked on various research projects for both the Department of Primary Industries and the University of Queensland.
